# Renal denervation

Intervention · id `cardio:renal-denervation` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: RDN; Renal sympathetic denervation

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

Renal denervation (RDN) is a catheter-based procedure that aims to lower blood pressure by interrupting the signals carried by the renal nerves, the nerves of the kidneys. The US device classification gives the purpose of the catheters as denervating the renal nerves to lower blood pressure. Two systems were approved for use in the United States in November 2023, one using ultrasound (P220023, 7 November 2023) and one using radiofrequency energy (P220026, 17 November 2023). Their original approval orders, the only ones read (later supplements were not), state an indication to reduce blood pressure as an adjunctive treatment in people with hypertension whose blood pressure lifestyle changes and medicines do not control well enough. A 2026 narrative review describes the evidence as showing a modest blood pressure effect; the page records the authors' view only and does not grade the trials.

## Technical summary

No MeSH descriptor was found: a MeSH descriptor-label lookup for renal denervation on 2026-11-18 returned no match. Product code QYI (Ablation Catheter, Renal Denervation, class 3) of the US device classification is on the device page. Evidence in this atlas: the openFDA classification record for QYI, the openFDA records of the original approvals P220023 and P220026 (supplements not read) and PMC13607768 (Journal of Cardiovascular Development and Disease, 2026; CC BY 4.0), read for its abstract and one passage on the approved systems. No trial, registry entry or guideline was read for this page; the review's statements on guidelines, coverage and other topics are not carried over.

## Claims, with the population each applies to

## Context: People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them

Recipient: Recipient not specified; Population: People with uncontrolled or resistant hypertension, as the review's title and abstract describe them in general terms. The passages read give no age group and no trial population.; Care setting: Not applicable (narrative review, not a study); Geography: Not stated for most passages; the approval sentence refers to the United States; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (narrative review)

### The authors of the same review state that, after a decade of controversy following the neutral SYMPLICITY HTN-3 trial, a coherent body of second-generation sham-controlled randomised evidence, generated with radiofrequency, endovascular ultrasound and perivascular alcohol platforms, has established a reproducible, modest and durable antihypertensive effect with a favourable safety profile. They list a direct comparison with newly approved pharmacotherapy and evidence of cardiovascular event reduction among questions that remain to be addressed.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with uncontrolled or resistant hypertension, as the review's title and abstract describe them in general terms. The passages read give no age group and no trial population.; Care setting: Not applicable (narrative review, not a study); Geography: Not stated for most passages; the approval sentence refers to the United States; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (narrative review)
- Limitations: These are the authors' own appraisal in a narrative review. No trial, effect size or safety figure was read for this page, and the review's own search ended in July 2026. The page records the authors' view and does not pool or grade the trials.
- Last checked: 2026-11-18
- Sources:
  1. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: Abstract, sentence 3, fragment 1 of 3. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.
  2. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: Abstract, sentence 3, fragment 2 of 3. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.
  3. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: Abstract, sentence 3, fragment 3 of 3. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.
  4. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: Abstract, sentence 6, fragment. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.

### A 2026 narrative review says catheter-based renal denervation interrupts efferent and afferent renal sympathetic signalling. It says two systems hold US Food and Drug Administration approval: the Paradise endovascular ultrasound system (Recor Medical), approved on 7 November 2023, and the SYMPLICITY Spyral radiofrequency system (Medtronic), approved on 17 November 2023.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with uncontrolled or resistant hypertension, as the review's title and abstract describe them in general terms. The passages read give no age group and no trial population.; Care setting: Not applicable (narrative review, not a study); Geography: Not stated for most passages; the approval sentence refers to the United States; Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (narrative review)
- Limitations: A narrative review by its authors, not a study. The approval dates agree with the openFDA records of P220023 and P220026 read for the device page. Other parts of the review, including its statements on guidelines and coverage, were not carried into this atlas.
- Last checked: 2026-11-18
- Sources:
  1. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: Abstract, sentence 2, fragment. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.
  2. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: 3. Device Platforms and Procedural Techniques, paragraph 1, sentence 1, fragment 1 of 2. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.
  3. Supports: Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-11-18. Narrative review published 7 September 2026. Only the abstract and one passage of section 3 are quoted in this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13607768/>
     Locator: 3. Device Platforms and Procedural Techniques, paragraph 1, sentence 1, fragment 2 of 2. Retrieved 2026-11-18T17:28:59Z. Source state: Current. Version fingerprint: f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df.
     How it applies: Quoted at this locator.

## Connected pages

- A 2026 review describes two US-approved renal denervation systems: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-pmc-rdn-review-systems` and its context]
- The same review gives the authors' appraisal of the sham-controlled evidence: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-pmc-rdn-review-evidence-appraisal` and its context]
- The procedure uses a renal denervation system: Renal denervation system (`cardio:renal-denervation-system`)
- Related condition page: Resistant hypertension (`cardio:resistant-hypertension`)
- Blood pressure medicines are described on their own page: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Filed under this front: Procedures and surgery (`cardio:front-procedures-and-surgery`)

## Provenance

Content hash: 9c470364d8b80cc7f257b5612a0dcaf1b03fbff15e6dcad5f5ae4c87a8048d50
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
